KX826 New Phase 3 Trial In China for 2025: 1.0% concentration Research/Science 1/10/2025
KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.
View this post in the Community →
Similar Community Posts Join
5 / 228 resultscommunity 1 year on fin. No results. I give up.
A user who has been taking finasteride, minoxidil, and microneedling for one year with no results, and the replies discuss other treatments, including dutasteride, which is feared due to potential side effects.
community First patient dosed with Pyrilutamide (Kintor) Phase III
First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia
Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
Related Research
6 / 33 results
research Comparison of Tissue Loss by Different Punches: A New A-Design
The new A-design punch for hair restoration surgery may lead to smaller scars compared to other types.
research Metabolic Syndrome and the Skin: A More Than Superficial Association
Some skin conditions may indicate metabolic syndrome, which could help with early detection and management of related health issues.
research Green Synthesis of Silver Nanoparticles Using Grewia Optiva Leaf Aqueous Extract and Isolated Compounds as Reducing Agent and Their Biological Activities
Silver nanoparticles made from Grewia optiva leaf extract show strong antibacterial, antioxidant, and hair growth benefits.
research Application of Amber Filler for Production of Novel Polyamide Composite Fiber
Adding amber particles to polyamide fibers makes them suitable for medical textiles like compression socks.
research Acutely Ill Patients in Internal Medicine Departments Want Treatment for Undiagnosed, Symptomatic Skin Conditions
Most hospitalized internal medicine patients have undiagnosed skin problems and want them treated.
research Metabolic Syndrome and Skin Disease: Potential Connection and Risk
Some skin diseases may indicate a higher risk of metabolic syndrome and related health issues.